Clinical trials: Cervical Cancer
Recurrent or Metastatic Nasopharyngeal Carcinoma
A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
This is a randomized, open-label, multi-center, phase III study to evaluate the efficacy and safety, and immunogenicity of MRG003 in combination with pucotenlimab in patients with recurrent or metastatic nasopharyngeal carcinoma.
- Trial name
- Magic-C002 (NCT06976190)
- Testing
- MRG003 + Pucotenlimab, Gemcitabine, Docetaxel, or Capecitabine
- Where
- China
- Volunteers
- 446 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Thyroid Nodules
Xiaojin Pill/Neixiao Luoli Pill for the Treatment of Thyroid Nodules
The goal of this clinical trial is to learn whether Xiaojin Pill or Neixiao Luoli Pill can safely treat thyroid nodules in adults aged 18 to 65 years with benign or low-risk thyroid nodules.
- Trial name
- NCT07340177
- Testing
- Xiaojin Pill, Neixiao Luoli Pill, Lifestyle Intervention
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Zhejiang Provincial People's Hospital
Head and Neck Cancer, Neoadjuvant Therapy
Application of MRI Radiomics Features in Neoadjuvant Therapy of Head and Neck Squamous Cell Carcinoma
Head and neck squamous cell carcinoma is the sixth most common malignant tumor in the world. Neoadjuvant therapy, including neoadjuvant chemotherapy and immunotherapy, is recommended for patients with locally advanced head and…
- Conditions
- Head and Neck Cancer, Neoadjuvant Therapy, Immunotherapy, Chemotherapy
- Trial name
- NCT06755567
- Testing
- MRI-based radiomics-clinical model
- Where
- China
- Volunteers
- 750 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Head and Neck Squamous Cell Carcinoma
Neoadjuvant Adebrelimab Plus Dalpiciclib in Head and Neck Squamous Cell Carcinoma
This study is a single arm phase II trial including 30 patients with III-IVB (according to the 8th edition of UICC/AJCC staging) locally advanced head and neck squamous cell carcinoma (HNSCC) eligible for resection, who receive…
- Trial name
- NCT06199271
- Testing
- Adebrelimab and dalpiciclib
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Zhongzheng Xiang
Cervical Cancer, Lung Cancer
Internet-based System for Cancer Patients to Self-report Toxicity
Cancer patients may develop side effects during treatment, such as nausea, pain, fatigue, diarrhea, constipation, or shortness of breath.
- Conditions
- Cervical Cancer, Lung Cancer, Prostate Cancer, Vaginal Cancer
- Trial name
- NCT00578006
- Testing
- Questioners, STAR website
- Where
- United States
- Volunteers
- 1,007 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cervical Cancer
Phase II Clinical Trial of Concurrent Chemoradiotherapy Combined Nimotuzumab for Stage IIB-IVA Cervical Cancer
The purpose of this phase II trial is to determine the feasibility and efficacy of nimotuzumab injection combined with concurrent chemoradiotherapy for initially inoperable locally advanced cervical cancer.
- Trial name
- NCT02705612
- Testing
- Cisplatin, External Beam Radiation Therapy, Internal Radiation Therapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Air Force Military Medical University, China
Head and Neck Squamous Cell Carcinoma
A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC
The purpose of the study is to determine the activity and safety of ACR-368 (prexasertib) in combination with gemcitabine in participants with Head and Neck Squamous Cell Carcinoma (HNSCC).
- Trial name
- NCT06597565
- Testing
- Gemcitabine, ACR-368
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Squamous Cell Carcinoma of the Head and Neck
A Study of Nivolumab in Participants With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO)
The purpose of the study is to capture the utilization of nivolumab among participants with squamous cell carcinoma of the head and neck (SCCHN) since its approval, and to describe the health related quality of life (HRQoL) among…
- Trial name
- VOLUME-PRO (NCT05068609)
- Testing
- Nivolumab
- Where
- United States
- Volunteers
- 509 people
- Sponsor
- Bristol-Myers Squibb
Cervical Cancer
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
The investigators propose to evaluate the efficacy of the combination of standard chemotherapy with bevacizumab with Pembrolizumab in women with recurrent, persistent, or metastatic cervical cancer.
- Trial name
- NCT03367871
- Testing
- Pembrolizumab, Paclitaxel, Cisplatin
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Miami
Esophageal Neoplasms
Study of Simultaneous Modulated Accelerated Radiation Therapy Concurrent With Chemotherapy to Treat Esophageal Cancer
The purpose of this study is to evaluate the acute and 2-year late toxicities, the 2-year local control and overall survival rates in patients with esophageal squamous cell carcinoma receiving simultaneous modulated accelerated…
- Trial name
- NCT01670409
- Testing
- SMART, PF
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Chuangzhen Chen
Oral Squamous Cell Carcinoma
A Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell Carcinoma
This prospective, single-center, randomized, controlled study will evaluate the efficacy and safety of TC Regimenwith or without nimotuzumab in recurrent metastatic oral squamous cell carcinoma.
- Trial name
- NCT04367909
- Testing
- Nimotuzumab, Docetaxel, Carboplatin
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Xin-Hua Xu
Cervical Cancer, Human Papillomavirus Infection
Effect of Health Belief Model-Based Education on Cervical Cancer Knowledge and HPV Vaccine Attitudes in Women
This study evaluated the effect of a Health Belief Model-based educational intervention on women's knowledge of cervical cancer and their attitudes and beliefs toward HPV vaccination.
- Conditions
- Cervical Cancer, Human Papillomavirus Infection, Preventive Health Services
- Trial name
- HBM-HPV (NCT07521163)
- Testing
- Health Belief Model-Based Education
- Where
- Turkey (Türkiye)
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Muhammet Faruk Yigit
Bacterial Infection
Effect of Oral Preparation on Bacterial Colonization of the Pharyngeal Mucosa in Surgery of Head and Neck Cancer
Surgical site infections are an important health indicator for hospitals and a significant medico-economic issue. The aim of the study is to assess the impact of chlorhexidine mouthwash performed before surgery on the bacterial…
- Trial name
- ORAL-ISO (NCT02753387)
- Testing
- Chlorhexidine, NaCl 0.9 %
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Rennes University Hospital
Nasopharyngeal Carcinoma
PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma
At present, the treatment regimen of locally advanced nasopharyngeal carcinoma still needs to be further improved, and the focus of improvement lies in "replacing cisplatin with high-efficiency and low-toxicity treatment…
- Trial name
- NCT05341193
- Testing
- Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab, Bevacizumab+Toripalimab+gemcitabine, adjuvant with Toripalimab
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Sun Yat-sen University
Paranasal Sinus Cancer, Nasal Cavity Tumor
A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages
This study is being done to test a new treatment plan for large tumors in the sinus or nasal cavity that will include endoscopic surgery plus chemotherapy and proton-beam radiation therapy.
- Conditions
- Paranasal Sinus Cancer, Nasal Cavity Tumor, Nasal Cavity Adenocarcinoma
- Trial name
- NCT03274414
- Testing
- Cisplatin, Adjuvant Proton Radiotherapy, Endoscopic Resection
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent / Metastatic Nasopharyngeal Cancer
To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer
This study is a single-arm, randomized, open-label, multi-cohort Phase Ib clinical trial. The experimental drug is TQB2858 Injection. The trial was divided into 3 cohorts.
- Trial name
- NCT05198531
- Testing
- TQB2858 Injection, Anlotinib Hydrochloride Capsule, Gemcitabine hydrochloride injection
- Where
- 7 sites in China
- Volunteers
- 90 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Cervical Cancer
EF5 to Detect Tumor Hypoxia in Patients With Stage IIB, Stage IIIB, or Stage IVA Cervical Cancer
RATIONALE: Knowing the level of oxygen in tumor tissue may help predict the effectiveness of anticancer therapy. EF5 may be effective in measuring oxygen in tumor tissue and helping to predict the effectiveness of anticancer…
- Trial name
- NCT00049231
- Testing
- EF5, immunohistochemistry staining method, biopsy
- Where
- 5 sites in United States
- Sponsor
- Gynecologic Oncology Group
Oral Mucositis
Comparative Efficacy of Rebamipide Gargle And Benzydamine HCL Gargle in Prevention and Management of Chemo- and Radio-therapy-induced Oral Mucositis
evaluate preventive and therapeutic effects of Rebamipide gargle on reducing incidence of oral mucositis in comparison with benzydamine HCL mouthwash.
- Trial name
- NCT04685395
- Testing
- Ribamipide gargle \benzdymine HCL gargel
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Cairo University
Nasopharyngeal Neoplasms
The Value of Diagnosis and Outcome Prediction in CTC for Metastatic NPC Patients
A circulating tumor cell (CTC) count is an established prognostic factor in some malignancies such as metastatic breast cancer. However, the value of CTC in diagnosis and outcome prediction of metastatic nasopharyngeal carcinoma…
- Trial name
- NCT02505139
- Testing
- the number of circulating tumor cells
- Volunteers
- 166 people
- Sponsor
- Sun Yat-sen University
Squamous Cell Carcinoma of the Head and Neck
FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel
The primary objective of the phase II trial is to determine the efficacy and safety of a combination of Durvalumab with the Carboplatin/Paclitaxel as first line treatment in patients with recurrent/metastatic SCCHN not eligible…
- Trial name
- FRAIL-IMMUNE (NCT03723967)
- Testing
- Durvalumab with Carboplatin/Paclitaxel
- Where
- 17 sites in France
- Volunteers
- 104 people
- Sponsor
- Centre Leon Berard